

THE WAY FORWARD FOR HTA COOPERATION THE VIEWS OF STAKEHOLDERS



Session 1 – Engaging with patients and clinicians on HTA: Current status and future direction

Eric Low
Chairman - Amyloidosis Research Consortium
Independent Healthcare Consultant



Background

Problem 1. Impeded and distorted market access

Problem 2. Duplication of work for national HTA bodies

Problem 3. Unsustainability of HTA cooperation

General objectives:


- Ensure a better functioning of the internal market;
- Contribute to a high level of human health protection.

Specific objectives:

- Improve the availability of innovative health technologies for EU patients;
- Ensure efficient use of resources and strengthen the quality of HTA across the EU;
- Improve business predictability.

Operational objectives:

- Promote convergence in HTA tools, procedures and methodologies;
- Reduce duplication of efforts for HTA bodies and industry;
- Ensure the use of joint outputs in Member States;
- Ensure the long-term sustainability of EU HTA cooperation.



High cost pressures on health care systems

Current model for healthcare and medicines development not sustainable

Value demonstration

Benefit – risk assessments

Patient centric models as an answer?

The regulator no longer final hurdle

Players move in isolation — multi stakeholder alignment?

Big Data


Trust & transparency

New societal contract required?

More networked and educated patients




Allocation of scarce resources



Uncertainty and value






Patients lose out – health systems buy costs not outcomes

The innovation gap








Bioscience: Lost in Translation? Richard Barker

Closing the innovation gap



The future



Bioscience: Lost in Translation? Richard Barker


Patient input to NICE Technology Appraisals



Patient organisations - consultation and workshop **Guidance Development** Patient organisations & patient experts – written submissions 1. Scoping Lay members - summary of patient issues Lay members - decision making discussions 2. Evidence submission Patient experts - answer questions and participate in discussion 3. Committee meeting 1 Meeting held in public Patient organisations - comment 4. Consultation Patient experts - comment Public – comment 5. Committee meeting 2 Lay members - decision making discussions Patient experts - exceptionally invited back Meeting held in public **6. Final Appraisal Determination** Patient organisations - comment on factual accuracies or can put in an appeal 7. Publication Plain English version for patients and carers 8. Review Patient organisations - decision to review


Assessing cost-effectiveness







Health Technology Assessment



Based on: IJzerman & Steuten, 2011

Slide acknowledgment: Janneke Grutters et al



Conclusion

- Collaboration in HTA across Europe is to be welcomed and will help improve efficiencies and timelines
- May have limited impact on improving access to new medicines etc.
- Patient input may have limited impact on decision-making other than at threshold but can provide helpful information on burden of disease and unmet needs etc.
- There must also be a focus on improving research and evidence generation to improve value proposition and reduce uncertainties
- This will help systems buy outcomes rather than costs

This is where patient involvement really matters